Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.49 |
| ▸ | IKBKB | O14920 | 10/20 | 0.49 |
| ▸ | FYN | P06241 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203218 | 0.92 | NTRK1 (0.49) | NTRK1IKBKBFYNHDAC3HDAC1 | |
| SCHEMBL1202966 | 0.92 | NTRK1 (0.50) | NTRK1IKBKBFYNHDAC3HDAC1 | |
| SCHEMBL1203842 | 0.90 | NTRK1 (0.48) | BRAFNTRK1IKBKBFYNNTRK3 | |
| SCHEMBL1203131 | 0.87 | FYN (0.53) | NTRK1FYNNTRK3NTRK2IRAK4 | |
| SCHEMBL1203062 | 0.84 | FYN (0.60) | NTRK1IKBKBFYNHDAC3HDAC1 | |
| SCHEMBL1202991 | 0.83 | FYN (0.48) | BRAFNTRK1IKBKBFYNNTRK3 | |
| SCHEMBL1203673 | 0.83 | NTRK1 (0.50) | NTRK1IKBKBFYNNTRK3NTRK2 | |
| SCHEMBL1202812 | 0.83 | PIM1 (0.49) | NTRK1IKBKBFYNNTRK3NTRK2 | |
| SCHEMBL1202618 | 0.82 | FYN (0.61) | NTRK1IKBKBFYNCHUKMAPK10 | |
| SCHEMBL1202657 | 0.82 | FYN (0.72) | NTRK1IKBKBFYNCHUKMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | BRAF 12/4885NTRK1 755/4885IKBKB 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.